198 related articles for article (PubMed ID: 29718226)
1. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis.
Burke KE; Khalili H; Garber JJ; Haritunians T; McGovern DPB; Xavier RJ; Ananthakrishnan AN
Inflamm Bowel Dis; 2018 Jul; 24(8):1840-1848. PubMed ID: 29718226
[TBL] [Abstract][Full Text] [Related]
2. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.
Barber GE; Yajnik V; Khalili H; Giallourakis C; Garber J; Xavier R; Ananthakrishnan AN
Am J Gastroenterol; 2016 Dec; 111(12):1816-1822. PubMed ID: 27596696
[TBL] [Abstract][Full Text] [Related]
3. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
4. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment.
Lee SH; Walshe M; Oh EH; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Greener T; Weizman AV; Silverberg MS; Ye BD
Inflamm Bowel Dis; 2021 Aug; 27(9):1452-1461. PubMed ID: 33269403
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
[TBL] [Abstract][Full Text] [Related]
6. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
Singh S; George J; Boland BS; Vande Casteele N; Sandborn WJ
J Crohns Colitis; 2018 May; 12(6):635-643. PubMed ID: 29370397
[TBL] [Abstract][Full Text] [Related]
7. Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease.
Karmi N; Bangma A; Spekhorst LM; van Dullemen HM; Visschedijk MC; Dijkstra G; Weersma RK; Voskuil MD; Festen EAM
PLoS One; 2021; 16(9):e0256860. PubMed ID: 34534227
[TBL] [Abstract][Full Text] [Related]
8. Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.
Yoon SM; Haritunians T; Chhina S; Liu Z; Yang S; Landers C; Li D; Ye BD; Shih D; Vasiliauskas EA; Ippoliti A; Rabizadeh S; Targan SR; Melmed GY; McGovern DPB
Inflamm Bowel Dis; 2017 Aug; 23(8):1382-1393. PubMed ID: 28590340
[TBL] [Abstract][Full Text] [Related]
9. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases.
Jung ES; Choi KW; Kim SW; Hübenthal M; Mucha S; Park J; Park Z; Ellinghaus D; Schreiber S; Franke A; Oh WY; Cheon JH
J Gastroenterol Hepatol; 2019 Oct; 34(10):1727-1735. PubMed ID: 30851117
[TBL] [Abstract][Full Text] [Related]
10. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.
Papamichael K; Baert F; Tops S; Assche GV; Rutgeerts P; Vermeire S; Gils A; Ferrante M
J Crohns Colitis; 2017 Jan; 11(1):53-59. PubMed ID: 27402915
[TBL] [Abstract][Full Text] [Related]
11. Artificial Neural Network Analysis-Based Immune-Related Signatures of Primary Non-Response to Infliximab in Patients With Ulcerative Colitis.
Chen X; Jiang L; Han W; Bai X; Ruan G; Guo M; Zhou R; Liang H; Yang H; Qian J
Front Immunol; 2021; 12():742080. PubMed ID: 34992592
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
[TBL] [Abstract][Full Text] [Related]
13. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease.
Dubinsky MC; Mei L; Friedman M; Dhere T; Haritunians T; Hakonarson H; Kim C; Glessner J; Targan SR; McGovern DP; Taylor KD; Rotter JI
Inflamm Bowel Dis; 2010 Aug; 16(8):1357-66. PubMed ID: 20014019
[TBL] [Abstract][Full Text] [Related]
14. A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn's Disease.
Li L; Chen R; Zhang Y; Zhou G; Chen B; Zeng Z; Chen M; Zhang S
Front Immunol; 2021; 12():646673. PubMed ID: 34367126
[TBL] [Abstract][Full Text] [Related]
15. Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis.
Yoshida A; Matsuoka K; Ueno F; Morizane T; Endo Y; Hibi T
Inflamm Intest Dis; 2021 May; 6(2):117-122. PubMed ID: 34124183
[TBL] [Abstract][Full Text] [Related]
16. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease.
Song JH; Hong SN; Lee JE; Kim K; Kim TJ; Kim ER; Chang DK; Kim YH
Scand J Gastroenterol; 2019 Jul; 54(7):876-885. PubMed ID: 31303093
[No Abstract] [Full Text] [Related]
17. A
Romero-Cara P; Torres-Moreno D; Pedregosa J; Vílchez JA; García-Simón MS; Ruiz-Merino G; Morán-Sanchez S; Conesa-Zamora P
Int J Med Sci; 2018; 15(1):10-15. PubMed ID: 29333082
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.
Netz U; Carter JV; Eichenberger MR; Dryden GW; Pan J; Rai SN; Galandiuk S
World J Gastroenterol; 2017 Jul; 23(27):4958-4967. PubMed ID: 28785150
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
[TBL] [Abstract][Full Text] [Related]
20. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
